Attending PAGE, WCOP or ACOP? take advantage of this special rate for Advanced Phoenix NLME courses

We are running our always popular advanced NLME course at a special rate of $1000 for a 2 day session before these three conferences; enter Discount code: "WCOP2016" for any of the 3 courses below. PAGE - 6-7 June 2016 WCOP - 19-20 August 2016 ACOP - 27-29 October 2016 Course name: "(CL-301) Advanced Pharmacometrics PK/PD Modeling Course using Phoenix NLME" Link: http://www.certarauniversity.com/lms/index.php?r=course/details&id7 Best regards, Simon. Get tips and discuss Phoenix with other users; https://support.certara.com/forums/ Topics covered include -Covariate Analysis - Random effect parameters -Between Subject variability -Between occasion variability Phoenix modelling language (PML) - Language through built in and graphical - Language through "edit as textual "mode only - Dobefore, doafter, while, double - Sequence statement - while(1), while(condition) - if statement - Simulate statement - Random number generators How does the program thinks Program stopping, when, why and implications Maximum a posteriori / Posthoc estimates Population Simulation Clinical trial designs Special simulation and fitting tools available in pml Simulate: unif(), norm() Fitting: lpois,lnegbin Literature based modeling and Simulation exercises Lelanidomide Population PK -Normal likelihood - Use of "edit as textual" based on built in and graphical template -Pk responses Population PKPD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy induced thrombocytopenia - Normal likelihood - Transit compartments -PK/PD responses Population PK/PD of homocysteine in the presence of Methotrexate - PK/PD/covariate analysis Population pharmacokinetics and exposure toxicity analysis of Vatalanib in patients with myelodysplastic syndromes - Standard Population PK analysis - Volume Kinetics for Infusion Fluids Target- mediated pharmacokinetic/pharmacodynamic model based meta-analysis and dosing regimen optimization of a long-acting release formulation of exenatide in patients with type 2 diabetes mellitus -Edit as textual - TMDD Etc. ___________________________________ Simon.Davis_at_certara.com Senior Scientific Consultant Pharsight- A CertaraT Company Work Mobile : +44 7500 190 212 >> note the new number! Facsimile : +1 801 991 7145 Personal Mobile : +44 7980 832 666 Phoenix 6.4 and Validation Suite available http://www.certara.com/support/product-downloads Sign up for the Certara blog at http://info.certara.com/roundtable ___________________________________ https://www.certara.com/training (some upcoming course in EU below, see website for US, India etc.) Intermediate PKPD with Phoenix (Tue-Fri) 16-19 May, Copenhagen, Denmark Advanced Phoenix NLME (Mon-Tue before PAGE) 6-7 June, Lisbon, Portugal Intro to Phoenix WinNonlin, 21-23 Sep 2016, Copenhagen, Denmark Intermediate PKPD with Phoenix (Tue-Fri) 18-21 Oct, London, UK Intro to Phoenix NLME (Tue-Wed) 15-16 Nov, Barcelona, Spain Intro to Phoenix WinNonlin, 5-7 Dec 2016, Frankfurt, Germany Intro to Phoenix IVIVC, 7-8 Dec 2016, Frankfurt, Germany